donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > VCEL Vericel > Detailed Quotes

VCEL Vericel

27.690
+0.610+2.25%
Trading Session 08/12 13:26 ET
High
28.040
Open
27.380
Turnover
3.67M
Low
27.145
Pre Close
27.080
Volume
132.67K
Market Cap
1.31B
P/E(TTM)
Loss
52wk High
60.240
Shares
47.18M
P/E(Static)
Loss
52wk Low
22.420
Float Cap
1.14B
Bid/Ask %
20.00%
Historical High
1589.999
Shs Float
41.08M
Volume Ratio
0.51
Historical Low
1.690
Dividend TTM
--
Div Yield TTM
550
P/B
7.47
Dividend LFY
--
Div Yield LFY
1986.28%
Turnover Ratio
0.32%
Amplitude
3.31%
Avg Price
27.672
Lot Size
1
Float Cap
1.14B
Bid/Ask %
20.00%
Historical High
1589.999
Shs Float
41.08M
Volume Ratio
0.51
Historical Low
1.690
Dividend TTM
--
P/B
7.47
Dividend LFY
--
Turnover Ratio
0.32%
Amplitude
3.31%
Avg Price
27.672
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
CEO: Colangelo Esq., Dominick C.
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...